Clinical study on neuroprotective effect of esketamine on patients with supratentorial tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073509

Enrollment

Unknown

Registered

2023-07-12

Start date

2023-07-24

Completion date

Unknown

Last updated

2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

supratentorial tumor

Interventions

Group NK:0.3mg/kg/h Esketamine

Group NS:Pumping normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18~60 2. ASA classification I ~ II; 3. Glasgow score before operation: 13-15 points; 4. Informed consent of patients.

Exclusion criteria

Exclusion criteria: 1. Allergy to the required narcotic drugs 2. Hypertension History 3. Renal and hepatic dysfunction 4. Myocardial infarction in the past 6 months 5. Congestive heart failure 6. A history of mental illness, drug and alcohol abuse; 7. Reoperation

Design outcomes

Primary

Measure	Time frame
S-100ß;NSE;HADS;	—

Secondary

Measure	Time frame
opioid administration;Mean arterial pressure;extubation time;anesthesia recovery time;	—

Countries

China

Contacts

Public ContactZhou Huanzhu

The 904th Hospital of PLA

Liaoxingzhi@aliyun.com+86 177 3814 8108

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026